Drug
Almonertinib
Almonertinib: highest development phase Phase 3, developed by Hansoh Pharmaceutical, United Therapeutics. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Hansoh Pharmaceutical, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Almonertinib NCT04500717 | Phase 3 | Non Small Cell Lung Cancer |
| Almonertinib NCT04841811 | Phase 3 | Lung Cancer |
| Almonertinib NCT04951635 | Phase 3 | Non-small Cell Lung Cancer |
| Almonertinib NCT04944069 | Not Applicable | NSCLC |
Latest
No recent events.
Follow Almonertinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.